BPC-157

Connective tissue is where BPC-157 has been studied most thoroughly. A 2025 systematic review covering 36 studies of musculoskeletal applications reported consistent improvements in functional, structural, and biomechanical outcomes after tendon ruptures, ligament tears, muscle injuries, and fractures (1). A separate 2025 narrative review reached similar conclusions, describing robust regenerative and cytoprotective effects across the connective-tissue literature (2).

The mechanism behind these effects appears to center on blood supply. Tendons and ligaments are notoriously slow to heal because they're poorly vascularized — there simply aren't many blood vessels reaching the tissue to deliver the cells and signals needed for repair. BPC-157 may help by promoting angiogenesis, the formation of new blood vessels, through a signaling pathway involving VEGFR2 (a receptor that triggers blood vessel growth) and the Akt-eNOS axis, which produces nitric oxide to relax and expand vessels (1, 2). It also engages ERK1/2 signaling, a pathway involved in cell proliferation and tissue rebuilding, and appears to upregulate growth hormone receptor expression — effectively making repair cells more responsive to the body's own healing signals (1).

A small retrospective study followed 16 patients who received intra-articular injections of BPC-157 — directly into the knee joint — for various types of knee pain, including osteoarthritis, meniscus issues, and ligament problems (3). Among the 12 patients who received BPC-157 alone, 11 (about 92%) reported significant improvement in pain. When the overall group was considered, including those who received BPC-157 combined with thymosin-beta-4, roughly 88% reported relief.

This was a small, uncontrolled chart review based on phone follow-up rather than a rigorous trial, so the findings are preliminary. But it's one of the few pieces of human data on BPC-157 to date, and the directional signal — that joint injection of the peptide may help with multiple types of knee pain — aligns with the broader preclinical picture of a compound that promotes repair in poorly vascularized tissue (3). Larger controlled studies would be needed to confirm the effect and clarify which knee conditions respond best.

Beyond connective tissue, BPC-157 has been studied for effects on the brain and spinal cord. A dedicated review summarized work showing the peptide may counteract neuronal damage following stroke-like events, support recovery of memory, locomotion, and coordination after brain injury, and accelerate functional recovery after spinal cord compression — including return of movement after compression injuries (4).

Mechanistically, the same themes recur: modulation of the nitric oxide system, support for blood vessel function in damaged tissue, and reduction of inflammation around injured nerves (4). The peptide also appears to interact with dopamine signaling pathways, which is why it's been examined in models of schizophrenia-like symptoms and movement disorders. The breadth of nervous-system findings has made BPC-157 a recurring subject of interest for neurological repair, though as with the rest of the literature, this work is largely preclinical.

Because BPC-157 was originally isolated from gastric juice, its effects on the digestive tract are arguably the most foundational part of its research story. A 2025 review covering its broader medical potential summarized findings across models of inflammatory bowel disease and various forms of gut injury, where the peptide appears to protect and restore the intestinal lining (5).

The same protective mechanisms that show up elsewhere — promoting new blood vessel formation, dampening inflammation, supporting the integrity of the tissue barrier — seem to operate in the gut as well. This is part of why BPC-157 is sometimes described as a "gut-brain axis" compound: the peptide that originated in the stomach appears to exert protective effects throughout the body, and the gut itself remains one of the tissues where its effects have been most consistently observed (5).

Reported side effects in the published research are minimal — across the preclinical literature and the small human studies available, no significant adverse effects have been documented (1, 2, 3, 5). Long-term safety in humans hasn't been formally characterized because large-scale clinical trials haven't been completed. Anecdotally, some users report mild local effects with injection (tingling, brief redness at the site) and occasional fatigue in the first few days of use, which typically resolves.

The body of BPC-157 evidence comes primarily from preclinical and laboratory work, with limited human clinical data so far.

BPC-157 was temporarily on the World Anti-Doping Agency's prohibited list in 2022 and remains banned in some professional sports — relevant context for competitive athletes regardless of its current status (5).